# Combination of Novel Therapies for CKD Comorbid Depression

Study · id `cardio:ct-nct04422652` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04422652](<https://clinicaltrials.gov/study/NCT04422652>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04422652

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 201 participants.

## Technical summary

Registry record NCT04422652. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-24 (actual); primary completion 2026-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 201 participants (planned count; ClinicalTrials.gov record NCT04422652, source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)
- Started: 2020-09-24 (actual) (ClinicalTrials.gov record NCT04422652, source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT04422652, source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)
- Completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT04422652, source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04422652, source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04422652-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combination of Novel Therapies for CKD Comorbid Depression
- Acronym: CONCORD
- Condition: Chronic Kidney Diseases
- Condition: Major Depressive Disorder
- Condition: End Stage Kidney Disease (ESRD)
- Intervention (Drug): Bupropion
- Intervention (Behavioral): Behavioral activation therapy
- Intervention (Drug): Placebo
- Intervention (Other): Clinical Management
- Lead sponsor: Stony Brook University
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Stony Brook University (`cardio:org-stony-brook-university`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: f1543ede7a13af90f490853c12ac4328c8408f2b0cc06bd19e64470a5ea113a4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
